Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.54 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.48 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.48 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | TRPV6 | Q9H1D0 | 1/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL803673 | 0.92 | CHRNB2 (0.58) | CHRNB2CHRNA4KDM4ECHRM2CHRM1 | |
| SCHEMBL803669 | 0.92 | CHRNB2 (0.60) | CHRNB2CHRNA4KDM4EALDH1A1CACNA1I | |
| SCHEMBL9211536 | 0.86 | CHRNB2 (0.56) | CHRNB2CHRNA4KDM4ECHRM2CHRM1 | |
| SCHEMBL23291216 | 0.83 | CHRNB2 (0.56) | CHRNB2CHRNA4KDM4ECHRM2CHRM1 | |
| SCHEMBL23291215 | 0.83 | CHRNB2 (0.56) | CHRNB2CHRNA4KDM4ECHRM2CHRM1 | |
| SCHEMBL803095 | 0.83 | HSD11B1 (0.47) | MAPTKMT2ASIGMAR1 | |
| SCHEMBL803677 | 0.83 | KAT2B (0.40) | KDM4EALDH1A1 | |
| SCHEMBL803083 | 0.83 | CCR3 (0.58) | ALDH1A1 | |
| SCHEMBL14393395 | 0.81 | CHRNB2 (0.60) | CHRNB2CHRNA4KDM4EALDH1A1CACNA1I | |
| SCHEMBL8430036 | 0.80 | CHRNB2 (0.64) | CHRNB2CHRNA4KDM4ECHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8680159-B2 | Bradykinin 1 receptor modulating compounds | GRUENENTHAL GMBH (DE) | 2014-03-25 | — | — | US | disclosed |
| US-20120071461-A1 | Substituted Benzamide Compounds | GRUENENTHAL GMBH (DE) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071461-A1 | Substituted Benzamide Compounds | BDKRB1, BDKRB2, HRH2 | CHRNB2 636/4885CHRNA4 720/4885KDM4E 2727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.